TU M2-PK在晚期非小细胞肺癌化疗疗效评价中的临床应用价值

摘要

目的 评估肿瘤型M2丙酮酸激酶(TU M2-PK)作为一种肿瘤标志物在晚期非小细胞肺癌化疗疗效中的临床价值.方法 检测43例晚期非小细胞肺癌化疗前及化疗后1周血浆TU M2-PK进行比较分析.结果 晚期非小细胞肺癌化疗后效果:部分缓解(PR)18例,疾病稳定(SD)19例,疾病进展(PD)6例.PR加SD共37例,化疗后较化疗前下降(P<0.05),PD化疗后较化疗前无明显下降(P>0.05).结论 TU M2-PK测定可作为晚期非小细胞肺癌化疗效果评估的有效指标.%Objective To investigate the clinical value of tumor type M2 pymvate kinase( TU M2-PK ) as an assessment indicator of chemotherapeutic effect in advanced non-small cell lung cancer( NSCLC ) patients. Methods 43 cases of advanced NSCLC with chemotherapy were enrolled into this study. The TU M2-PK in the plasma a week before and after chemotherapy were compared and analyzed. Results partial remission ( PR ) occurred in 18 cases, stable disease ( SD ) in 19 cases and progressive disease ( PD ) in 6 cases. The level of TU M2-PK in PR and PD cases ( the total was 37 cases ) significantly declined after treatment compared with before treatment ( P < 0. 05 ). There was no obvious decrease in PD cases between pre-treatment and post-treatment ( P >0. 05 ). Conclusion TU M2-PK can be used as an effective assessment indicator of chemotherapeutic effect in advanced non-small cell lung cancel( NSCLC ) patients.